Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNYSE:CBM
Previous Symbol
CUSIP13201110
Phone201-804-3000
Debt
Debt-to-Equity Ratio0.49
Current Ratio4.54
Quick Ratio3.41
Price-To-Earnings
Trailing P/E Ratio15.08
Forward P/E Ratio16.95
P/E Growth1.73
Sales & Book Value
Annual Sales$534.46 million
Price / Sales3.00
Cash Flow$4.1314 per share
Price / Cash11.57
Book Value$19.64 per share
Price / Book2.43
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins22.67%
Return on Equity22.20%
Return on Assets14.86%
Miscellaneous
Employees1,228
Outstanding Shares33,560,000
Market Cap$1.64 billion
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The company's revenue for the quarter was down 7.1% on a year-over-year basis. During the same period last year, the firm posted $0.55 earnings per share. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus estimate of $2.79.
What price target have analysts set for CBM?
4 analysts have issued 12-month price objectives for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they expect Cambrex's stock price to reach $69.25 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
News headlines about CBM stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cambrex earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Nektar Therapeutics (NKTR), Amneal Pharmaceuticals (AMRX), Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO) and Agios Pharmaceuticals (AGIO).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 52)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
- Mr. Tom G. Vadaketh, Former Exec. VP & CFO (Age 55)
Who are Cambrex's major shareholders?
Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.23%), William Blair Investment Management LLC (7.54%), Bank of New York Mellon Corp (4.51%), Dimensional Fund Advisors LP (4.22%), Jackson Square Partners LLC (3.18%) and American Capital Management Inc. (2.17%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which institutional investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Tributary Capital Management LLC, Panagora Asset Management Inc., Janus Henderson Group PLC, Prudential Financial Inc., Rice Hall James & Associates LLC, Cambiar Investors LLC and Jackson Square Partners LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.
Which institutional investors are buying Cambrex stock?
CBM stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Acadian Asset Management LLC, William Blair Investment Management LLC, Copper Rock Capital Partners LLC, Oak Ridge Investments LLC, LSV Asset Management, BlackRock Inc. and Monarch Partners Asset Management LLC. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $47.80.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.64 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
